BTKi Treatment for CLL: A Patient Information Guide
A new patient guide from Johnson & Johnson, developed in collaboration with patient representatives from the CLL Advocates Network and with input from healthcare providers, is available now and offers, easily explained, much-needed and up to date support for people living with chronic lymphocytic leukaemia (CLL).
This digital resource focuses on Bruton’s tyrosine kinase inhibitors (BTKis) – a modern, targeted treatment that helps slow disease progression and improve quality of life.
BTKis may be used in the first-line or relapsed setting and can be given on their own or in combination with other anti-cancer medicines. They are usually taken once or twice daily as tablets for as long as the treatment is working. This guide explains how they work, what to expect during treatment, and how to manage side effects. It also highlights the importance of staying in touch with your healthcare team and caring for emotional wellbeing.
BTKi Treatment for CLL: A Patient Information Guide:
This resource will be useful for our member organisations to share with their patient community and will also offer value to individual patients with CLL and their care partners, who seek further information about BTKi treatments.
Clinicians are encouraged to share this guide with patients as a trusted resource that complements in-clinic discussions and helps individuals make informed decisions about their care.